{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:48:10Z","timestamp":1761598090270,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T00:00:00Z","timestamp":1561593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T00:00:00Z","timestamp":1561593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18fk0108008","JP18fk0108008"],"award-info":[{"award-number":["JP18fk0108008","JP18fk0108008"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Candida<\/jats:italic> peritonitis is a crucial disease, however the optimal antifungal therapy regimen has not been clearly defined. Peritoneal fibrosis (PF) can be caused by abdominal surgery, intra-abdominal infection, and malignant diseases, and is also widely recognized as a crucial complication of long-term peritoneal dialysis. However, the influence of PF on <jats:italic>Candida<\/jats:italic> peritonitis prognosis remains unknown. Here, we evaluated the severity of <jats:italic>Candida<\/jats:italic> peritonitis within the context of PF and the efficacy of micafungin using mice. A PF mouse model was generated by intraperitoneally administering chlorhexidine gluconate. <jats:italic>Candida<\/jats:italic> peritonitis, induced by intraperitoneal inoculation of <jats:italic>Candida albicans<\/jats:italic>, was treated with a 7-day consecutive subcutaneous administration of micafungin. <jats:italic>Candida<\/jats:italic> infection caused a higher mortality rate in the PF mice compared with the control mice on day 7. Proliferative <jats:italic>Candida<\/jats:italic> invasion into the peritoneum and intra-abdominal organs was confirmed pathologically only in the PF mice. However, all mice in both groups treated with micafungin survived until day 20. Micafungin treatment tends to suppress inflammatory cytokines in the plasma 12\u2009h after infection in both groups. Our results suggest that PF enhances early mortality in <jats:italic>Candida<\/jats:italic> peritonitis. Prompt initiation and sufficient doses of micafungin had good efficacy for <jats:italic>Candida<\/jats:italic> peritonitis, irrespective of the underlying PF.<\/jats:p>","DOI":"10.1038\/s41598-019-45776-x","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T10:02:45Z","timestamp":1561629765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of Candida peritonitis with underlying peritoneal fibrosis and efficacy of micafungin in murine models of intra-abdominal candidiasis"],"prefix":"10.1038","volume":"9","author":[{"given":"Nobuyuki","family":"Ashizawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0962-5758","authenticated-orcid":false,"given":"Taiga","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0696-5386","authenticated-orcid":false,"given":"Takahiro","family":"Takazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Saijo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Obata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Shimamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Koji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Izumikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Yanagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,27]]},"reference":[{"key":"45776_CR1","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1093\/ndt\/gfi159","volume":"20","author":"A Grassmann","year":"2005","unstructured":"Grassmann, A., Gioberge, S., Moeller, S. & Brown, G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 20, 2587\u20132593, https:\/\/doi.org\/10.1093\/ndt\/gfi159 (2005).","journal-title":"Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"45776_CR2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1681\/ASN.2011060607","volume":"23","author":"AK Jain","year":"2012","unstructured":"Jain, A. K., Blake, P., Cordy, P. & Garg, A. X. Global trends in rates of peritoneal dialysis. J Am Soc Nephrol 23, 533\u2013544, https:\/\/doi.org\/10.1681\/ASN.2011060607 (2012).","journal-title":"J Am Soc Nephrol"},{"key":"45776_CR3","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1093\/ndt\/gfq194","volume":"25","author":"T Shimaoka","year":"2010","unstructured":"Shimaoka, T. et al. Quantitative evaluation and assessment of peritoneal morphologic changes in peritoneal dialysis patients. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 25, 3379\u20133385, https:\/\/doi.org\/10.1093\/ndt\/gfq194 (2010).","journal-title":"Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"45776_CR4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00795-016-0133-8","volume":"49","author":"S Abe","year":"2016","unstructured":"Abe, S. et al. Chondroitin sulfate prevents peritoneal fibrosis in mice by suppressing NF-kappaB activation. Med Mol Morphol 49, 144\u2013153, https:\/\/doi.org\/10.1007\/s00795-016-0133-8 (2016).","journal-title":"Med Mol Morphol"},{"key":"45776_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/j.ajkd.2011.03.022","volume":"58","author":"M Burke","year":"2011","unstructured":"Burke, M. et al. Relapsing and recurrent peritoneal dialysis-associated peritonitis: a multicenter registry study. American journal of kidney diseases: the official journal of the National Kidney Foundation 58, 429\u2013436, https:\/\/doi.org\/10.1053\/j.ajkd.2011.03.022 (2011).","journal-title":"American journal of kidney diseases: the official journal of the National Kidney Foundation"},{"key":"45776_CR6","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1053\/ajkd.2002.33403","volume":"39","author":"ES Finkelstein","year":"2002","unstructured":"Finkelstein, E. S. et al. Patterns of infection in patients maintained on long-term peritoneal dialysis therapy with multiple episodes of peritonitis. American journal of kidney diseases: the official journal of the National Kidney Foundation 39, 1278\u20131286, https:\/\/doi.org\/10.1053\/ajkd.2002.33403 (2002).","journal-title":"American journal of kidney diseases: the official journal of the National Kidney Foundation"},{"key":"45776_CR7","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1007\/s00134-013-3109-3","volume":"39","author":"M Bassetti","year":"2013","unstructured":"Bassetti, M. et al. A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med 39, 2092\u20132106, https:\/\/doi.org\/10.1007\/s00134-013-3109-3 (2013).","journal-title":"Intensive Care Med"},{"key":"45776_CR8","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00134-015-3866-2","volume":"41","author":"M Bassetti","year":"2015","unstructured":"Bassetti, M. et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med 41, 1601\u20131610, https:\/\/doi.org\/10.1007\/s00134-015-3866-2 (2015).","journal-title":"Intensive Care Med"},{"key":"45776_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0272-6386(96)90135-3","volume":"28","author":"SJ Goldie","year":"1996","unstructured":"Goldie, S. J. et al. Fungal peritonitis in a large chronic peritoneal dialysis population: a report of 55 episodes. American journal of kidney diseases: the official journal of the National Kidney Foundation 28, 86\u201391 (1996).","journal-title":"American journal of kidney diseases: the official journal of the National Kidney Foundation"},{"key":"45776_CR10","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/j.1469-0691.2010.03360.x","volume":"17","author":"P Montravers","year":"2011","unstructured":"Montravers, P., Mira, J. P., Gangneux, J. P., Leroy, O. & Lortholary, O. A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect 17, 1061\u20131067, https:\/\/doi.org\/10.1111\/j.1469-0691.2010.03360.x (2011).","journal-title":"Clin Microbiol Infect"},{"key":"45776_CR11","doi-asserted-by":"publisher","first-page":"e0153247","DOI":"10.1371\/journal.pone.0153247","volume":"11","author":"P Vergidis","year":"2016","unstructured":"Vergidis, P. et al. Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment. PLoS One 11, e0153247, https:\/\/doi.org\/10.1371\/journal.pone.0153247 (2016).","journal-title":"PLoS One"},{"key":"45776_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3747\/pdi.2016.00078","volume":"36","author":"PK Li","year":"2016","unstructured":"Li, P. K. et al. ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment. Perit Dial Int 36, 481\u2013508, https:\/\/doi.org\/10.3747\/pdi.2016.00078 (2016).","journal-title":"Perit Dial Int"},{"issue":"1","key":"45776_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/jof4010027","volume":"4","author":"Cornelius Clancy","year":"2018","unstructured":"Clancy, C. J. & Nguyen, M. H. Non-Culture Diagnostics for Invasive Candidiasis: Promise and Unintended Consequences. J Fungi (Basel) 4, https:\/\/doi.org\/10.3390\/jof4010027 (2018).","journal-title":"Journal of Fungi"},{"key":"45776_CR14","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas, P. G. et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 62, e1\u201350, https:\/\/doi.org\/10.1093\/cid\/civ933 (2016).","journal-title":"Clin Infect Dis"},{"key":"45776_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ijantimicag.2014.06.007","volume":"44","author":"M Castanheira","year":"2014","unstructured":"Castanheira, M., Messer, S. A., Jones, R. N., Farrell, D. J. & Pfaller, M. A. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. Int J Antimicrob Agents 44, 320\u2013326, https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.06.007 (2014).","journal-title":"Int J Antimicrob Agents"},{"key":"45776_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1128\/AAC.44.1.57-62.2000","volume":"44","author":"S Tawara","year":"2000","unstructured":"Tawara, S. et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrobial agents and chemotherapy 44, 57\u201362 (2000).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"45776_CR17","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1086\/599039","volume":"48","author":"DL Horn","year":"2009","unstructured":"Horn, D. L. et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 48, 1695\u20131703, https:\/\/doi.org\/10.1086\/599039 (2009).","journal-title":"Clin Infect Dis"},{"key":"45776_CR18","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/jac\/dkx444","volume":"73","author":"F Lamoth","year":"2018","unstructured":"Lamoth, F., Lockhart, S. R., Berkow, E. L. & Calandra, T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother 73, i4\u2013i13, https:\/\/doi.org\/10.1093\/jac\/dkx444 (2018).","journal-title":"J Antimicrob Chemother"},{"key":"45776_CR19","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1128\/CMR.00029-06","volume":"20","author":"MA Pfaller","year":"2007","unstructured":"Pfaller, M. A. & Diekema, D. J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20, 133\u2013163, https:\/\/doi.org\/10.1128\/CMR.00029-06 (2007).","journal-title":"Clin Microbiol Rev"},{"key":"45776_CR20","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1086\/501020","volume":"42","author":"PH Chandrasekar","year":"2006","unstructured":"Chandrasekar, P. H. & Sobel, J. D. Micafungin: a new echinocandin. Clin Infect Dis 42, 1171\u20131178, https:\/\/doi.org\/10.1086\/501020 (2006).","journal-title":"Clin Infect Dis"},{"key":"45776_CR21","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1177\/0091270005279580","volume":"45","author":"MF Hebert","year":"2005","unstructured":"Hebert, M. F. et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 45, 1145\u20131152, https:\/\/doi.org\/10.1177\/0091270005279580 (2005).","journal-title":"J Clin Pharmacol"},{"key":"45776_CR22","doi-asserted-by":"publisher","first-page":"e0180050","DOI":"10.1371\/journal.pone.0180050","volume":"12","author":"CH Lee","year":"2017","unstructured":"Lee, C. H. et al. Efficacy and safety of micafungin versus extensive azoles in the prevention and treatment of invasive fungal infections for neutropenia patients with hematological malignancies: A meta-analysis of randomized controlled trials. PLoS One 12, e0180050, https:\/\/doi.org\/10.1371\/journal.pone.0180050 (2017).","journal-title":"PLoS One"},{"key":"45776_CR23","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/ndt\/11.3.498","volume":"11","author":"SJ Davies","year":"1996","unstructured":"Davies, S. J., Bryan, J., Phillips, L. & Russell, G. I. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 11, 498\u2013506 (1996).","journal-title":"Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"45776_CR24","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1681\/ASN.V132470","volume":"13","author":"JD Williams","year":"2002","unstructured":"Williams, J. D. et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 13, 470\u2013479 (2002).","journal-title":"J Am Soc Nephrol"},{"key":"45776_CR25","doi-asserted-by":"publisher","first-page":"e0183013","DOI":"10.1371\/journal.pone.0183013","volume":"12","author":"CR Harlow","year":"2017","unstructured":"Harlow, C. R. et al. Targeting lysyl oxidase reduces peritoneal fibrosis. PloS one 12, e0183013, https:\/\/doi.org\/10.1371\/journal.pone.0183013 (2017).","journal-title":"PloS one"},{"key":"45776_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.rbmo.2010.04.021","volume":"21","author":"G Pados","year":"2010","unstructured":"Pados, G., Venetis, C. A., Almaloglou, K. & Tarlatzis, B. C. Prevention of intra-peritoneal adhesions in gynaecological surgery: theory and evidence. Reproductive biomedicine online 21, 290\u2013303, https:\/\/doi.org\/10.1016\/j.rbmo.2010.04.021 (2010).","journal-title":"Reproductive biomedicine online"},{"key":"45776_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.biopha.2017.01.039","volume":"88","author":"ZD Lv","year":"2017","unstructured":"Lv, Z. D. et al. Blocking TGF-beta1 by P17 peptides attenuates gastric cancer cell induced peritoneal fibrosis and prevents peritoneal dissemination in vitro and in vivo. Biomedicine & pharmacotherapy\u2009=\u2009Biomedecine & pharmacotherapie 88, 27\u201333, https:\/\/doi.org\/10.1016\/j.biopha.2017.01.039 (2017).","journal-title":"Biomedicine & pharmacotherapy\u2009=\u2009Biomedecine & pharmacotherapie"},{"key":"45776_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/path.4942","volume":"243","author":"A Capobianco","year":"2017","unstructured":"Capobianco, A., Cottone, L., Monno, A., Manfredi, A. A. & Rovere-Querini, P. The peritoneum: healing, immunity, and diseases. The Journal of pathology 243, 137\u2013147, https:\/\/doi.org\/10.1002\/path.4942 (2017).","journal-title":"The Journal of pathology"},{"key":"45776_CR29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/089686080302300102","volume":"23","author":"Y Mishima","year":"2003","unstructured":"Mishima, Y. et al. Enhanced expression of heat shock protein 47 in rat model of peritoneal fibrosis. Perit Dial Int 23, 14\u201322 (2003).","journal-title":"Perit Dial Int"},{"key":"45776_CR30","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1016\/j.actbio.2012.03.050","volume":"8","author":"Y Obata","year":"2012","unstructured":"Obata, Y. et al. HSP47 siRNA conjugated with cationized gelatin microspheres suppresses peritoneal fibrosis in mice. Acta biomaterialia 8, 2688\u20132696, https:\/\/doi.org\/10.1016\/j.actbio.2012.03.050 (2012).","journal-title":"Acta biomaterialia"},{"key":"45776_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11255-014-0829-4","volume":"47","author":"J Wang","year":"2015","unstructured":"Wang, J. et al. A review of rodent models of peritoneal dialysis and its complications. International urology and nephrology 47, 209\u2013215, https:\/\/doi.org\/10.1007\/s11255-014-0829-4 (2015).","journal-title":"International urology and nephrology"},{"key":"45776_CR32","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1111\/j.1523-1755.2004.00935.x","volume":"66","author":"Y Yoshio","year":"2004","unstructured":"Yoshio, Y. et al. TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. Kidney Int 66, 1677\u20131685, https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00935.x (2004).","journal-title":"Kidney Int"},{"key":"45776_CR33","doi-asserted-by":"publisher","unstructured":"Zhao, Y. et al. Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model. Antimicrobial agents and chemotherapy 61, https:\/\/doi.org\/10.1128\/AAC.01009-17 (2017).","DOI":"10.1128\/AAC.01009-17"},{"key":"45776_CR34","doi-asserted-by":"publisher","first-page":"7601","DOI":"10.1128\/AAC.04134-14","volume":"58","author":"RK Shields","year":"2014","unstructured":"Shields, R. K., Nguyen, M. H., Press, E. G. & Clancy, C. J. Abdominal candidiasis is a hidden reservoir of echinocandin resistance. Antimicrobial agents and chemotherapy 58, 7601\u20137605, https:\/\/doi.org\/10.1128\/AAC.04134-14 (2014).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"45776_CR35","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1681\/ASN.2009070694","volume":"21","author":"O Devuyst","year":"2010","unstructured":"Devuyst, O., Margetts, P. J. & Topley, N. The pathophysiology of the peritoneal membrane. J Am Soc Nephrol 21, 1077\u20131085, https:\/\/doi.org\/10.1681\/ASN.2009070694 (2010).","journal-title":"J Am Soc Nephrol"},{"key":"45776_CR36","first-page":"669","volume":"27","author":"H Chaudhry","year":"2013","unstructured":"Chaudhry, H. et al. Role of cytokines as a double-edged sword in sepsis. In Vivo 27, 669\u2013684 (2013).","journal-title":"In Vivo"},{"key":"45776_CR37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.trsl.2006.07.001","volume":"148","author":"K Kinoshita","year":"2006","unstructured":"Kinoshita, K., Iwasaki, H., Uzui, H. & Ueda, T. Candin family antifungal agent micafungin (FK463) modulates the inflammatory cytokine production stimulated by lipopolysaccharide in THP-1 cells. Translational research: the journal of laboratory and clinical medicine 148, 207\u2013213, https:\/\/doi.org\/10.1016\/j.trsl.2006.07.001 (2006).","journal-title":"Translational research: the journal of laboratory and clinical medicine"},{"key":"45776_CR38","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1128\/AAC.01159-07","volume":"52","author":"J Mitsuyama","year":"2008","unstructured":"Mitsuyama, J. et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrobial agents and chemotherapy 52, 1318\u20131324, https:\/\/doi.org\/10.1128\/AAC.01159-07 (2008).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"45776_CR39","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1128\/AAC.02124-15","volume":"60","author":"A Lepak","year":"2015","unstructured":"Lepak, A., Marchillo, K., VanHecker, J., Azie, N. & Andes, D. Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic\/Pharmacodynamic Study with Humanized Doses in Mice. Antimicrobial agents and chemotherapy 60, 674\u2013677, https:\/\/doi.org\/10.1128\/AAC.02124-15 (2015).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"45776_CR40","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1128\/AAC.00673-06","volume":"51","author":"J Keirns","year":"2007","unstructured":"Keirns, J. et al. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults. Antimicrobial agents and chemotherapy 51, 787\u2013790, https:\/\/doi.org\/10.1128\/AAC.00673-06 (2007).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"45776_CR41","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1128\/AAC.00478-08","volume":"52","author":"DR Andes","year":"2008","unstructured":"Andes, D. R., Diekema, D. J., Pfaller, M. A., Marchillo, K. & Bohrmueller, J. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrobial agents and chemotherapy 52, 3497\u20133503, https:\/\/doi.org\/10.1128\/AAC.00478-08 (2008).","journal-title":"Antimicrobial agents and chemotherapy"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45776-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45776-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45776-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T10:48:32Z","timestamp":1671274112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45776-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,27]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["45776"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-45776-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2019,6,27]]},"assertion":[{"value":"18 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.M. has received research grants from Astellas, Pfizer, MSD, and Asahi Kasei; K. Yamamoto and T.N. from MSD; K.I. and H.M. from Astellas, Pfizer, MSD, Sumitomo Dainippon, and Asahi Kasei; K. Yanagihara and S.K. from Astellas, Pfizer, MSD, Sumitomo Dainippon, Asahi Kasei, and Janssen. The remaining authors have no potential conflicts of interest. The authors alone are responsible for the content and writing of the paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9331"}}